Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 438 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings Classification · 85% confidence The document is a substantive on-site inspection report prepared by the sponsor (中信证券) regarding its continuous supervision (“持续督导”) of the listed company 益方生物科技 for the 2025 period, in accordance with Shanghai Stock Exchange self-regulation guidelines. It includes detailed findings on corporate governance, internal controls, information disclosure, related-party transactions, use of raised funds, and operational status. It is not an annual report, earnings release, proxy statement, or other defined category but rather a regulatory compliance filing. There is no bespoke category for a sponsor’s continuous supervision inspection report, so it falls under the generic Regulatory Filings category.
2026-05-11 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 72% confidence The document is a continuous supervision annual follow-up report issued by the sponsor (CITIC Securities) for a sci-tech board listed company, containing regulatory compliance checks, risk disclosures, on-site inspections, financial data and related legal/litigation updates. It is not an AGM presentation, earnings release, annual/interim report by the company’s management, nor a simple announcement—it is a specific compliance document required by the exchange. It falls under the miscellaneous/regulatory filings category as there is no dedicated category for continuous supervision reports.
2026-05-11 Chinese
益方生物第二届董事会2026年第四次会议决议公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement by the company’s board of directors detailing the resolutions passed at its 2026 fourth meeting (e.g., approval of reports, profit distribution plan, incentive plans, and authorizations). It does not introduce a change in board composition or senior management (so not MANG), nor is it a financial report itself (10-K, IR, ER) or an investor presentation (IP), nor is it simply announcing a report (RPA). It is a regulatory corporate filing conveying board meeting outcomes that does not fit a more specific category, so it defaults to a general regulatory filing (RNS).
2026-04-14 Chinese
益方生物关于2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分（第二批）第二个归属期符合归属条件的公告
Share Issue/Capital Change Classification · 85% confidence The document is a regulatory announcement by a listed company on the Shanghai Stock Exchange detailing the vesting conditions met and the number of restricted shares under its 2022 equity incentive plan that will be issued and registered. It is not an earnings release, proxy, board change, or management discussion. Instead, it announces a capital change via share issuance to employees under a restricted stock plan, matching the “Share Issue/Capital Change” category (Code: SHA).
2026-04-14 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2025年度募集资金存放与实际使用情况的专项核查意见
Capital/Financing Update Classification · 81% confidence The document is titled as a sponsor’s “专项核查意见” (special inspection opinion) regarding the deposit and actual use of 2025 fundraising proceeds following the company’s IPO. It comprehensively details the fundraising amount, account storage, usage breakdown, cash management, project investment, and audit opinions. This is not a general annual or interim report, earnings release, or governance code, but a targeted compliance update on the proceeds from the equity issuance. The most fitting category is “Capital/Financing Update” (CAP), as it pertains to post-issuance use of raised capital.
2026-04-14 Chinese
益方生物2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 87% confidence The document is a standalone audit performance evaluation report (“2025年度会计师事务所履职情况评估报告”) detailing the auditor’s credentials, risk capacity, litigation history, resource allocation, audit plan, quality control, and information security processes. It is not an Annual Report or earnings release, nor an announcement of publication. It fits the definition of a detailed audit information report, so the correct category is Audit Report / Information (AR).
2026-04-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.